Impact of Osteoporosis on the Risk of Dementia in Almost 60,000 Patients Followed in General Practices in Germany

August 20, 2018 - Frankfurt, Germany – Osteoporosis is estimated to affect 200 million women across the world. In Germany, the prevalence of this chronic disease among people aged 50 years and older is around 15%. In recent decades, several authors have analyzed the impact of osteoporosis on the risk of cognitive decline, but most of these studies have been conducted outside Europe. More...

August 20, 2018

Experts Highlight New Concepts and Approaches to the Rehabilitation of Stroke

Global experts on pediatric brain injury report on the significant challenges, key issues, and proposed solutions to support children and youth when they transition to school in this special issue of NeuroRehabilitation

August 13, 2018 - Amsterdam, NL – Stroke remains a leading cause of adult disability, and the global burden of stroke continues to grow with devastating consequences for patients, families, and caregivers. In this special issue of NeuroRehabilitation leading international experts on stroke rehabilitation provide theoretical and practical insights into the steps necessary to push beyond merely compensatory training and onto a level of recovery that is satisfactory for patients. More...

August 13, 2018

Insulin Resistance Under-Diagnosed in Non-Diabetics with Parkinson’s Disease

Findings could lead to increased screening for PD patients to detect and correct insulin resistance, reports the Journal of Parkinson’s Disease

August 3, 2018 - Amsterdam, NL – Almost two-thirds of non-diabetic patients with Parkinson’s disease (PD) may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson’s Disease. Their findings suggest that insulin resistance in PD is a common and largely undetected problem, especially in patients who are overweight. More...

August 3, 2018

Exenatide Treatment Alleviated Symptoms of Depression in Patients with Moderate Parkinson’s Disease

Post hoc analysis of PD trial results showed exenatide improved non-motor symptoms, including depression, according to a new report in the Journal of Parkinson’s Disease

August 1, 2018 - Amsterdam, NL – Non-motor symptoms of Parkinson’s disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits. In a post hoc analysis of the exenatide-PD trial results, investigators found that patients on exenatide treatment experienced improvements in severity of depression, independent of whether their motor function improved. More...

August 1, 2018